Pipeline — registered trials by phase
SECURE®-C Cervical Artificial Disc Clinical Study/ SECURE-C Cervical Artificial Disc Postmarket Approval Study
— · Symptomatic Cervical Disc Disease · Completed · est. 2010-04
A Retrospective Review: Outcomes of the REFLECT™ System for Idiopathic Scoliosis
— · Idiopathic Scoliosis · Not Yet Recruiting · est. 2027-01-30
INDEPENDENCE Spacer for Lumbar Fusion
— · Degenerative Disc Disease · Completed · est. 2016-08
TRIUMPH Lumbar Artificial Disc IDE: A Pilot Study
— · Lumbar Degenerative Disc Disease · Completed · est. 2016-12
Study of an Expandable Interbody Device for the Lumbar Spine
— · Degenerative Disc Disease · Completed · est. 2016-11
Amnios™ RT Outcomes Study
— · Plantar Fasciitis · Completed · est. 2022-11-30
A Pivotal Study of a Facet Replacement System to Treat Spinal Stenosis
— · Lumbar Spinal Stenosis · Completed · est. 2017-08
REFLECT Scoliosis System Post Approval Study
— · Idiopathic Scoliosis · Recruiting · est. 2027-03-31
Treatment of Sacroiliac Dysfunction With SI-LOK® Sacroiliac Joint Fixation SI-SI-LOK
— · Joint Dysfunction · Completed · est. 2018-07-05
A Retrospective Study Using CALIBER® TLIF Expandable Spacer in the Treatment of DDD: 2 Year Follow-up.
— · Degenerative Disc Disease · Completed · est. 2015-01
No registered trials in this stage.
No registered trials in this stage.
No registered trials in this stage.
No approved products listed under this sponsor in Drugs@FDA (partnered or subsidiary products may be listed elsewhere).
Source: ClinicalTrials.gov (trials where Globus Medical is lead sponsor; 10 active or completed) and Drugs@FDA (0 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- 10-Q2026-08-06Quarterly report
- 8-K2026-08-06Current report (material event)
- 8-K2026-06-04Current report (material event)
- SD2026-05-27SD
- 10-Q2026-05-07Quarterly report
- 8-K2026-05-07Current report (material event)
- SCHEDULE 13G2026-04-30SCHEDULE 13G
- DEFA14A2026-04-24DEFA14A
- DEF 14A2026-04-24Proxy statement
- SCHEDULE 13G/A2026-03-26SCHEDULE 13G/A
- 8-K2026-03-23Current report (material event)
- 10-K2026-02-24Annual report
- 8-K2026-02-24Current report (material event)
- 8-K2026-01-07Current report (material event)
- 10-Q2025-11-06Quarterly report
- 8-K2025-11-06Current report (material event)
- 10-Q2025-08-07Quarterly report
- 8-K2025-08-07Current report (material event)
- 8-K2025-07-21Current report (material event)
- 8-K2025-06-05Current report (material event)
- SD2025-05-29SD
- 8-K2025-05-15Current report (material event)
- SCHEDULE 13G/A2025-05-14SCHEDULE 13G/A
- 10-Q2025-05-08Quarterly report
- 8-K2025-05-08Current report (material event)
- DEFA14A2025-04-25DEFA14A
- DEF 14A2025-04-25Proxy statement
- SCHEDULE 13G/A2025-04-24SCHEDULE 13G/A
- 8-K2025-04-03Current report (material event)
- 10-K2025-02-20Annual report
- 8-K2025-02-20Current report (material event)
- SCHEDULE 13G/A2025-02-14SCHEDULE 13G/A
- 8-K2025-02-06Current report (material event)
- SCHEDULE 13G/A2025-02-05SCHEDULE 13G/A
- 8-K2025-01-08Current report (material event)
- SC 13G/A2024-11-14Large holder update
- 10-Q2024-11-05Quarterly report
- 8-K2024-11-05Current report (material event)
- UPLOAD2024-10-04UPLOAD
- CORRESP2024-10-02CORRESP
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.